Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation.
B cells
Sjøgren's syndrome
autoimmune diseases
Journal
Annals of the rheumatic diseases
ISSN: 1468-2060
Titre abrégé: Ann Rheum Dis
Pays: England
ID NLM: 0372355
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
04
11
2019
revised:
09
07
2020
accepted:
10
07
2020
pubmed:
28
8
2020
medline:
15
12
2020
entrez:
27
8
2020
Statut:
ppublish
Résumé
Primary Sjögren's syndrome (pSS) is characterised by chronic hyperactivation of B lymphocytes. Salivary gland epithelial cells (SGECs) could play a role in promoting B-lymphocyte activation within the target tissue. We aimed to study the interactions between SGECs from patients with pSS or controls and B lymphocytes. Patients had pSS according to 2016 European League Against Rheumatism/American College of Rheumatology criteria. Gene expression analysis of SGECs and B lymphocytes from pSS and controls isolated from salivary gland biopsies and blood was performed by RNA-seq. SGECs from pSS and controls were cocultured with B-lymphocytes sorted from healthy donor blood and were stimulated. Transwell and inhibition experiments were performed. Gene expression analysis of SGECs identified an upregulation of interferon signalling pathway and genes involved in immune responses ( SGECs from patients with pSS had better ability than those from controls to induce survival and activation of B lymphocytes. Targeting a single cytokine did not inhibit this effect, whereas leflunomide, BTK or PI3K inhibitors partially decreased B-lymphocyte viability in this model. This gives indications for future therapeutic options in pSS.
Identifiants
pubmed: 32843324
pii: annrheumdis-2019-216588
doi: 10.1136/annrheumdis-2019-216588
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1468-1477Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AT, NA and MM are employed by Biogen. XM received an honorarium for consultancy advice on Sjögren’s syndrome from BMS, GSK, Novartis and Servier and a research grant from Servier. The rest of the authors declare that they have no relevant conflicts of interest.